ECEun-Young Choi

Eun-Young Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eun-Young Choi has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of gestational age by pregnancy outcomes and distribution of pregnancy-related codes in Korean claims data

    by Woo-Jung Kim, Yunha Noh, Yongtai Cho, Eun-Young Choi, HyunJoo Lim, Hyesung Lee, Ju-Young Shin

    OBJECTIVES: This study aimed to evaluate a fixed-duration algorithm for gestational age (GA) estimation according to pregnancy outcomes and to describe the GA distribution of pregnancy-related codes in Korea.METHODS: We included 351,055 pregnancy episodes (2019–2022) from linked data between the National Health Insurance Service and the Korea Immunization Registry Information System (KIRIS). GA from claims data was estimated by subtracting fixed durations from the delivery date (algorithm-based GA), and GA derived from KIRIS was defined as the gold standard. Accuracy was evaluated as the proportion of episodes in which the difference between the estimated GA and the reference standard fell within ±2 weeks. We described the distributions of the GA at which each prenatal test, pregnancy complication, and diagnostic code was recorded.RESULTS: Algorithm-based GA estimation showed high accuracy for live births (92.2% within ±2 weeks) but markedly lower accuracy for non-live birth outcomes, including stillbirth (3.3%), termination (7.2%), spontaneous abortion (45.2%), and ectopic pregnancy (20.0%). In additional analyses aimed at identifying potential indicators for improving GA estimation, most events occurred within clinically expected timeframes, although some individual codes exhibited poor temporal alignment.CONCLUSIONS: Algorithm-based GA estimation using claims data performed well for live births but demonstrated limited accuracy for non-live birth outcomes. Incorporating information from prenatal tests and pregnancy complications may enhance GA estimation.


  • Open Access

    Antirheumatic medication use among pregnant women with rheumatoid arthritis: a Norwegian nationwide drug utilisation study

    by Eun-Young Choi, Marleen M H J van Gelder, Benjamin P Geisler, In-Sun Oh, Hedvig M E Nordeng


  • Open Access

    Real‐World Effectiveness and Safety of Recombinant Human Follicle‐Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study

    by Joong Yeup Lee, Eun‐Young Choi, Jung Ryeol Lee, Young Sik Choi, Ji Hyang Kim, Chang‐Woo Choo, Yunju Choe, Hee‐Jin Seo, Hyesung Lee, Yujeong Shin, et al.

    Despite widespread rhFSH use in infertile women undergoing ART, real‐world comparative data on its effectiveness and safety across different rhFSH types remain limited. Using the HIRA claims database, we included 10,684 women aged 20–39 with infertility (2016–2021) who used only rhFSH in their first in vitro fertilization–embryo transfer (IVF‐ET). Outcome variables comprised effectiveness (≥ 11 oocytes retrieved, pregnancy rates and live birth rate) and safety (ectopic pregnancy, miscarriage, preterm birth and ovarian hyperstimulation syndrome [OHSS]) in the whole cohort, further categorized into follitropin and other rhFSH. Baseline characteristics were described, and relative risks (RR) with 95% confidence intervals (CI) were estimated using a generalized linear model, adjusting for age and imbalanced variables. Of 10,684 patients prescribed rhFSH, 7.1% were aged 20–29, 41.6% were 30–34, and 51.3% were 35–39. ICSI was utilized in 57.7% of cycles, and 76.8% used the GnRH antagonist protocol. The live birth rate was 38.8%, and the OHSS rate was 5.9%. Comparing baseline characteristics of the follitropin ( n = 2,594) and other rhFSH group ( n = 8,090), ICSI (62.2% vs. 56.3%) and GnRH antagonist protocol (81.3% vs. 75.3%) were more common in the follitropin group. Women who received follitropin were more likely to have ≥ 11 oocytes retrieved (adjusted RR, 1.09; 95% CI: 1.02–1.16) and less likely to have OHSS (adjusted RR, 0.73; 95% CI: 0.60–0.90). These findings provide real‐world evidence supporting rhFSH effectiveness and safety in fresh IVF cycles, with follitropin potentially offering advantages in oocyte retrieval and reduced OHSS rates.

  • Open Access

    Exposure to antibiotics during pregnancy or early infancy and the risk of autoimmune disease in children: A nationwide cohort study in Korea

    by Eun-Young Choi, Sungho Bea, Hyesung Lee, Ahhyung Choi, Jung Yeol Han, Eun Ha Kang, Ju-Young Shin

    Background: Emerging evidence suggests that prenatal or early-life exposure to antibiotics may contribute to the development of autoimmune diseases in children. However, previous studies investigating this association have yielded conflicting and inconclusive results, partly due to challenges related to confounding by indication and underlying genetic or familial factors. Methods and findings: A nationwide cohort study was conducted using mother-child linked claims database of Korea’s National Health Insurance Service between 2008 and 2021. Among individuals with diagnosis of infections, children exposed to antibiotics during pregnancy or early infancy were compared to those who were not exposed. The autoimmune-related outcomes of interest were the onset of type 1 diabetes, juvenile idiopathic arthritis, inflammatory bowel disease (ulcerative colitis, Crohn’s disease), systemic lupus erythematosus, and Hashimoto’s thyroiditis. The antibiotic-exposed pregnancies were compared to unexposed pregnancies using inverse probability of treatment weighting (IPTW) methods to adjust for potential imbalances and confounding by indication. Also, sibling-matched analyses were performed to minimize bias from within-family confounders. Cox proportional hazard model was applied to assess associations, and clinically relevant subgroup analyses, including sex, subclasses and exposed timing of antibiotics were also conducted. Before IPTW, we identified 1,516,574 exposed children and 1,186,516 unexposed children for pregnancy analysis, and 1,925,585 exposed and 1,421,464 unexposed for the infancy analysis. In the pregnancy analysis within the infection-restricted population, IPTW analyses showed null association between antibiotic exposure and autoimmune diseases, including type 1 diabetes (IPTW HR 1.14, 95% CI [0.96, 1.35], p-value = 0.132), juvenile idiopathic arthritis (HR 1.02, 95% CI [0.85, 1.22], p-value = 0.830), ulcerative colitis (HR 1.02, 95% CI [0.76, 1.37], p-value = 0.895), Crohn’s disease (HR 1.16, 95% CI [0.98, 1.36], p-value = 0.076), systemic lupus erythematosus (HR 0.70, 95% CI [0.49, 1.01], p-value = 0.053), and Hashimoto’s thyroiditis (HR 1.06, 95% CI [0.91, 1.23], p-value = 0.448). In the infancy analysis within the infection-restricted population, IPTW analyses showed no substantial differences in autoimmune disease risk between exposed and non-exposed groups for type 1 diabetes (IPTW HR 1.05, 95% CI [0.88, 1.26], p-value = 0.594) and juvenile idiopathic arthritis (HR 1.11, 95% CI [0.93, 1.33], p-value = 0.253), ulcerative colitis (HR 0.95, 95% CI [0.67, 1.36], p-value = 0.776), Crohn’s disease (HR 1.07, 95% CI [0.91, 1.25], p-value = 0.403), systemic lupus erythematosus (HR 1.46, 95% CI [0.95, 2.26], p-value = 0.087), and Hashimoto’s thyroiditis (HR 1.14, 95% CI [0.97, 1.33], p-value = 0.104). These results also showed similar associations in sibling-matched analyses. Subgroup analyses showed that maternal use of cephalosporins or antibiotics during first or second trimester was associated with a small increased risk of Crohn’s disease in pregnancy analysis, while antibiotic exposure in males or during the first two months of life was associated with a modestly increased risk of autoimmune thyroiditis in infancy analysis. The primary limitations of this study include potential residual confounding due to unmeasured variables. Conclusions: In this nationwide cohort study, we found no association between early-life antibiotic exposure and the overall risk of autoimmune diseases in children. These findings underscore the importance of ensuring that antibiotic use during pregnancy and early infancy is guided by clear clinical indications and highlight the need for further research to explore subgroup-specific risks in greater detail.


  • Open Access

    Global Trends in Analgesic Opioid Use in Pregnancy: A Retrospective Cohort Study

    by Jonathan Brett, Carolyn E. Cesta, Malcolm B. Gillies, Brian T. Bateman, Adrienne Y. L. Chan, Michael C.-Y. Cheng, Yongtai Cho, Ey Pharm D Choi, Jacqueline M. Cohen, Sarah Donald, et al.

    Background: Pain is common during pregnancy, yet there are few contemporary studies of opioid use in pregnancy. This study aimed to describe prescription analgesic opioid use during pregnancy across four regions: Oceania (New South Wales, Australia, and New Zealand), North America (Ontario, Canada, and United States), Northern Europe (Denmark, Finland, Iceland, Norway, Sweden, and United Kingdom), and East Asia (Hong Kong, South Korea, and Taiwan). Methods: A common protocol was applied to population-based data to measure analgesic opioid dispensing or prescriptions during pregnancy before birth in 2000 to 2020. The populations captured included those with public and private insurance in the United States, a sample of primary care practices in the United Kingdom, and whole-of-population cohorts in the remainder of the locations. This study examined prevalence of use, defined as at least one dispensing or prescribing and estimated trends over time. Use by sociodemographic and pregnancy characteristics is described. Results: Among a total of 20,306,228 pregnancies, 1,115,853 (55 per 1,000) had at least one analgesic opioid dispensing or prescription, ranging from 4 per 1,000 in the United Kingdom to 191 per 1,000 in the U.S. publicly insured population. The greatest relative decrease in prevalence was observed in Hong Kong (prevalence ratio, 0.2; 95% CI, 0.1 to 0.2 between 2005 and 2020), and the greatest increase was in Iceland (prevalence ratio, 4.4; 95% CI, 3.7 to 5.2 between 2004 and 2017). Codeine and tramadol were among the three most prevalent opioids in most populations. In a sensitivity analysis defining opioid use as two or more opioid -dispensing or -prescribing events, the prevalence of opioid use across populations was 17 per 1,000. Conclusions: In this large multinational study, wide global variation in the prevalence of analgesic opioid use in pregnancy was observed, yet patterns of use by sociodemographic and pregnancy characteristics were relatively consistent. Analgesic opioid use remained stable or downward trending over time in most, but not all, countries.


  • Open Access

    Prenatal and Infant Exposure to Acid-Suppressive Medications and Risk of Allergic Diseases in Children

    by Yunha Noh, Han Eol Jeong, Ahhyung Choi, Eun-Young Choi, Björn Pasternak, Hedvig Nordeng, Mette Bliddal, Kenneth K. C. Man, Ian C. K. Wong, Dong Keon Yon, et al.

    The prevalence of allergic diseases has risen worldwide, especially among children and adolescents.1,2 Great efforts have been dedicated to identifying factors associated with allergic disease,3 and data have suggested associations between allergic diseases and acid-suppressive medication (ASM) use in fetal and early life.4-8 Meanwhile, ASMs, including proton pump inhibitors (PPIs) and histamine 2 receptor antagonists (H2RAs), are frequently used during pregnancy to treat gastroesophageal reflux disease (GERD),9 and in recent decades, the use of ASMs has substantially increased in both pregnant and pediatric populations.10,11


  • Open Access

    Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study

    by Eun-Young Choi, Han Eol Jeong, Yunha Noh, Ahhyung Choi, Dong Keon Yon, Jung Yeol Han, Ji-Hee Sung, Seung-Ah Choe, Ju-Young Shin

    Background: Existing data on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during late pregnancy is well established, providing assurance. However, the use of NSAIDs during early pregnancy remains inconclusive owing to conflicting findings on adverse neonatal outcomes as well as the limited data on adverse maternal outcomes. Therefore, we sought to investigate whether early prenatal exposure to NSAIDs was associated with neonatal and maternal adverse outcomes. Methods and findings: We conducted a nationwide, population-based cohort study using Korea’s National Health Insurance Service (NHIS) database with a mother–offspring cohort constructed and validated by the NHIS to include all live births in women aged 18 to 44 years between 2010 and 2018. We defined exposure to NSAIDs as at least two records of NSAID prescriptions during early pregnancy (first 90 days of pregnancy for congenital malformations and first 19 weeks for nonmalformation outcomes) and compared against three distinct referent groups of (1) unexposed, no NSAID prescription during the 3 months before pregnancy start to end of early pregnancy; (2) acetaminophen-exposed, at least two acetaminophen prescriptions during early pregnancy (i.e., active comparator); and (3) past users, at least two NSAID prescriptions before the start of pregnancy but no relevant prescriptions during pregnancy. Outcomes of interest were adverse birth outcomes of major congenital malformations and low birth weight and adverse maternal outcomes of antepartum hemorrhage and oligohydramnios. We estimated relative risks (RRs) with 95% CIs using generalized linear models within a propensity score (PS) fine stratification weighted cohort that accounted for various potential confounders of maternal sociodemographic characteristics, comorbidities, co-medication use, and general markers of burden of illness. Of 1.8 million pregnancies in the PS weighted analyses, exposure to NSAIDs during early pregnancy was associated with slightly increased risks for neonatal outcomes of major congenital malformations (PS-adjusted RR, 1.14 [CI, 1.10 to 1.18]) and low birth weight (1.29 [1.25 to 1.33]), and for maternal outcome of oligohydramnios (1.09 [1.01 to 1.19]) but not antepartum hemorrhage (1.05 [0.99 to 1.12]). The risks of overall congenital malformations, low birth weight, and oligohydramnios remained significantly elevated despite comparing NSAIDs against acetaminophen or past users. Risks of adverse neonatal and maternal outcomes were higher with cyclooxygenase-2 selective inhibitors or use of NSAIDs for more than 10 days, whereas generally similar effects were observed across the three most frequently used individual NSAIDs. Point estimates were largely consistent across all sensitivity analyses, including the sibling-matched analysis. Main limitations of this study are residual confounding by indication and from unmeasured factors. Conclusions: This large-scale, nationwide cohort study found that exposure to NSAIDs during early pregnancy was associated with slightly higher risks of neonatal and maternal adverse outcomes. Clinicians should therefore carefully weigh the benefits of prescribing NSAIDs in early pregnancy against its modest, but possible, risk of neonatal and maternal outcomes, where if possible, consider prescribing nonselective NSAIDs for <10 days, along with continued careful monitoring for any safety signals.


  • Open Access

    Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations

    by Ahhyung Choi, Yunha Noh, Han Eol Jeong, Eun-Young Choi, Kenneth K. C. Man, Jung Yeol Han, Hyun-Soo Kim, Dong Keon Yon, Ju-Young Shin

    Gastroesophageal reflux disease (GERD) is common during pregnancy, occurring in up to 80% of the pregnant population.1 Although mild symptoms can be alleviated by lifestyle modifications, acid-suppressive medications are often required for a substantial number of patients to manage their inadequately controlled symptoms. Specifically, the use of proton pump inhibitors (PPIs) during pregnancy has increased worldwide, which may be in part due to their acid-suppressing effects.2,3